Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q73135203)
Watch
English
An overview of the use of non-steroidal aromatase inhibitors in the treatment of breast cancer
scientific article published on 01 September 2000
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed ID
11056331
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11056331%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 November 2019
title
An overview of the use of non-steroidal aromatase inhibitors in the treatment of breast cancer
(English)
1 reference
stated in
Europe PubMed Central
PubMed ID
11056331
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11056331%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 November 2019
author name string
A Buzdar
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed ID
11056331
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11056331%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 November 2019
publication date
1 September 2000
1 reference
stated in
Europe PubMed Central
PubMed ID
11056331
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11056331%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 November 2019
published in
European Journal of Cancer
1 reference
stated in
Europe PubMed Central
PubMed ID
11056331
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11056331%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 November 2019
volume
36 Suppl 4
1 reference
stated in
Europe PubMed Central
PubMed ID
11056331
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11056331%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 November 2019
page(s)
S82-4
1 reference
stated in
Europe PubMed Central
PubMed ID
11056331
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11056331%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 November 2019
cites work
Endocrine aspects of the clinical management of breast cancer - current issues
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900238-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900238-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900238-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900238-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900238-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900238-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900238-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0959-8049(00)00238-0
1 reference
stated in
Europe PubMed Central
PubMed ID
11056331
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11056331%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 November 2019
PubMed ID
11056331
1 reference
stated in
Europe PubMed Central
PubMed ID
11056331
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11056331%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 November 2019
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit